Technical Trend Shift and Price Movement
The stock, currently priced at ₹8,457.85, closed down 1.38% from its previous close of ₹8,576.10 on 29 Apr 2026. The intraday range saw a high of ₹8,570.00 and a low of ₹8,402.00, reflecting volatility within a relatively narrow band. Astrazeneca Pharma India Ltd’s 52-week high stands at ₹10,653.05, while the 52-week low is ₹6,501.60, indicating a significant range of price movement over the past year.
Technically, the trend has deteriorated from mildly bearish to outright bearish, signalling increased selling pressure. Daily moving averages reinforce this negative momentum, with the stock trading below key averages, suggesting a lack of short-term buying interest. The bearish daily moving averages align with the weekly MACD indicator, which remains bearish, while the monthly MACD is mildly bearish, indicating that momentum is weakening across multiple timeframes.
Momentum Indicators: MACD, RSI, and KST Analysis
The Moving Average Convergence Divergence (MACD) indicator is a critical momentum gauge. On a weekly basis, it signals bearish momentum, confirming the recent downward price action. The monthly MACD, while only mildly bearish, suggests that longer-term momentum is also under pressure but not decisively negative. This divergence between weekly and monthly MACD readings highlights a potential for short-term weakness within a longer-term consolidation phase.
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in neutral territory. This lack of RSI confirmation means the stock is neither oversold nor overbought, which could imply that the current bearish momentum has room to extend before a potential reversal or relief rally.
Interestingly, the Know Sure Thing (KST) indicator presents a mixed picture: mildly bullish on the weekly timeframe but mildly bearish on the monthly. This suggests some short-term positive momentum attempts that are being offset by longer-term weakness, reinforcing the notion of a stock caught between conflicting technical forces.
Bollinger Bands and On-Balance Volume (OBV) Insights
Bollinger Bands add further nuance to the technical outlook. Weekly Bollinger Bands are bearish, indicating that the stock price is trending towards the lower band, a sign of increased volatility and downward pressure. Conversely, the monthly Bollinger Bands are bullish, suggesting that over a longer horizon, the stock may be consolidating or preparing for a potential rebound.
The On-Balance Volume (OBV) indicator, which measures buying and selling pressure, is mildly bearish on both weekly and monthly charts. This confirms that volume trends are not supporting a strong upward move, and selling pressure is subtly outweighing buying interest.
Dow Theory and Broader Market Context
According to Dow Theory, the weekly chart shows no clear trend, while the monthly chart is mildly bearish. This lack of a definitive trend on the weekly scale suggests indecision among investors, whereas the monthly mild bearishness aligns with the overall cautious stance. The stock’s recent Mojo Grade downgrade from Hold to Sell on 2 Jan 2026 reflects this technical deterioration and the cautious outlook from MarketsMOJO analysts.
Despite the current technical challenges, Astrazeneca Pharma India Ltd’s long-term returns remain impressive. Over the past 10 years, the stock has delivered a staggering 637.00% return, significantly outperforming the Sensex’s 200.30% gain. Even over three and five years, the stock has outpaced the benchmark with returns of 165.14% and 107.99%, respectively. However, more recent performance shows a slight underperformance, with a year-to-date return of -6.13% compared to the Sensex’s -9.78%, and a one-year return of -4.97% versus the Sensex’s -4.15%.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Market Capitalisation and Sector Positioning
Astrazeneca Pharma India Ltd is classified as a small-cap stock within the Pharmaceuticals & Biotechnology sector. This positioning often entails higher volatility and sensitivity to sector-specific developments. The pharmaceutical sector has been under pressure due to regulatory scrutiny and pricing challenges, which may be contributing to the stock’s recent technical weakness.
Investors should note that the stock’s current Mojo Score of 37.0 and a Sell grade reflect a cautious stance by MarketsMOJO analysts, who have downgraded the stock from Hold as of 2 Jan 2026. This downgrade is consistent with the technical indicators signalling increased bearish momentum and the lack of strong bullish confirmation from momentum oscillators.
Technical Outlook and Investor Considerations
The convergence of bearish signals from daily moving averages, weekly MACD, and Bollinger Bands suggests that Astrazeneca Pharma India Ltd is facing downward pressure in the near term. The absence of RSI signals and mixed KST readings imply that the stock may experience sideways movement or further declines before any meaningful recovery.
Given the stock’s recent underperformance relative to the Sensex on a one-year and year-to-date basis, investors should exercise caution. The mild bearishness in volume trends and Dow Theory assessments further reinforce the need for a prudent approach. Long-term investors may find value in the stock’s historical outperformance, but short-term traders should be wary of the prevailing technical headwinds.
Holding Astrazeneca Pharma India Ltd from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary and Strategic Implications
In summary, Astrazeneca Pharma India Ltd’s technical parameters have shifted towards a bearish outlook, with key indicators such as MACD and moving averages signalling increased selling momentum. The lack of RSI confirmation and mixed KST readings suggest that the stock may not yet be oversold, leaving room for further downside or consolidation.
Investors should weigh the stock’s strong long-term performance against its recent technical deterioration and sector challenges. The downgrade to a Sell grade by MarketsMOJO underscores the need for caution, particularly for short-term traders and those with lower risk tolerance. Monitoring volume trends and key support levels will be critical in assessing whether the stock can stabilise or if further declines are imminent.
Ultimately, Astrazeneca Pharma India Ltd remains a stock with significant historical gains but currently faces technical headwinds that warrant a measured and analytical approach to investment decisions.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
